| Parameters | Details |
|---|---|
| Category of Drug | Actinomycin D is an Antineoplastic antibiotic drug. |
| Mechanism of Action | It binds strongly, but reversibly, to DNA, interfering with the synthesis of RNA. Thus, it prevents RNA polymerase elongation and, consequently, inhibits protein synthesis. |
| Indications | Actinomycin D is used for 1. Trophoblastic tumors 2. Wilm’s tumor 3. Ewing’s sarcoma 4. Rhabdomyosarcoma |
| Synonyms | Actinomycin I Chounghwamycin B Actinomycin Actinomycin A-IV |
| Structure (1) |  |
| IUPAC Name | 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide |
| Molecular details | Molecular Formula- C62H86N12O16 Molecular Weight- 1255.4 g/mol |
| Well Known Pharmaceutical Brands | DACILON-CELON ACTINOCIN- NEON |
| Pharmacokinetic properties | 1. Absorption- poorly absorbed from the GI tract. 2. Plasma protein binding- 5%. 3. Slightly metabolized 4. plasma half-life – 36 hours 5. elimination half-life- 36 to 48 hours. |
| Available dosage forms | INJECTION |
| Dose | Adult and child above 6 months- 15 μg/kg/day. |
| Contraindications | 1. Hypersensitivity 2. lactation 3. Infection with children 4. Herpes zoster 5. Pregnancy |
| Adverse Effects | 1. Hair loss 2. Nausea 3. Vomiting 4. Mouth sores 5. Diarrhoea |
| Pregnancy Category | D |
